Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial-Reference-Cited by-同舟云学术

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

Published:2022-08 Issue:8 Volume:23 Page:1044-1054
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Pautier Patricia,Italiano Antoine,Piperno-Neumann Sophie,Chevreau Christine,Penel Nicolas,Firmin Nelly,Boudou-Rouquette Pascaline,Bertucci François,Balleyguier Corinne,Lebrun-Ly Valérie,Ray-Coquard Isabelle,Kalbacher Elsa,Bardet Aurélie,Bompas Emmanuelle,Collard Olivier,Isambert Nicolas,Guillemet Cécile,Rios Maria,Archambaud Baptiste,Duffaud Florence,ITALIANO Antoine,PAUTIER Patricia,LECESNE Axel,PIPERNO-NEUMANN Sophie,CHEVREAU Christine,CUPISSOL Didier,PENEL Nicolas,ALEXANDRE Jérôme,BERTUCCI François,RAY-COQUARD Isabelle,LEBRUN-LY Valérie,KALBACHER Elsa,DUFFAUD Florence,DELCAMBRE Corinne,BOMPAS Emmanuelle,COLLARD Olivier,ISAMBERT Nicolas,GUILLEMET Cécile,SOULIE Patrick,RIOS Maria,SAADA-BOUZID Esma

Funder

Merck

Roche

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing;Ducimetière;PLoS One,2011

2. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial;Judson;Lancet Oncol,2014

3. Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group

4. Differential gene expression in leiomyosarcoma;Skubitz;Cancer,2003

5. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Doxorubicin and trabectedin for recurrent leiomyosarcoma – A case report;Gynecologic Oncology Reports;2024-10

2. A Late-Arriving but Welcome Advance in Sarcoma Therapy;New England Journal of Medicine;2024-09-05

3. Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma;New England Journal of Medicine;2024-09-05

4. New strategies in soft tissue sarcoma treatment;Journal of Hematology & Oncology;2024-09-02

5. Histology-Tailored Approach to Soft Tissue Sarcoma;Annals of Surgical Oncology;2024-08-22